郑娟娟,司月乔,杨德忠,刘渔凯,王红勇,曾春雨,王伟.经导管主动脉瓣植入术治疗重度主动脉瓣狭窄[J].中国介入影像与治疗学,2023,20(11):650-653
经导管主动脉瓣植入术治疗重度主动脉瓣狭窄
Transcatheter aortic valve implantation for treating severe aortic stenosis
投稿时间:2023-01-30  修订日期:2023-07-09
DOI:10.13929/j.issn.1672-8475.2023.11.003
中文关键词:  主动脉瓣狭窄  心脏瓣膜假体植入  治疗转归
英文关键词:aortic valve stenosis  heart valve prosthesis implantation  treatment outcome
基金项目:
作者单位E-mail
郑娟娟 陆军军医大学大坪医院心血管内科, 重庆 400042
陆军军医大学西南医院老年科, 重庆 400038 
 
司月乔 陆军军医大学大坪医院心血管内科, 重庆 400042  
杨德忠 陆军军医大学大坪医院心血管内科, 重庆 400042  
刘渔凯 陆军军医大学大坪医院心血管内科, 重庆 400042  
王红勇 陆军军医大学大坪医院心血管内科, 重庆 400042  
曾春雨 陆军军医大学大坪医院心血管内科, 重庆 400042  
王伟 陆军军医大学大坪医院心血管内科, 重庆 400042
陆军军医大学西南医院老年科, 重庆 400038 
weiericwang@163.com 
摘要点击次数: 387
全文下载次数: 290
中文摘要:
      目的 观察经导管主动脉瓣植入术(TAVI)治疗重度主动脉瓣狭窄(AS)的效果。方法 回顾性收集18例接受TAVI的重度AS患者,记录TAVI即刻成功率,观察治疗过程中及治疗后相关并发症;随访记录治疗后1、3个月瓣膜功能及心血管事件。结果 18例实施TAVI成功。对3例AS合并冠心病患者行一站式TAVI+经皮冠状动脉介入治疗,对2例冠状动脉阻塞高风险患者通过“烟囱”或“开窗”技术加以预保护。1例顽固性心力衰竭患者接受体外膜氧合器辅助下TAVI;1例尿毒症患者于TAVI前、后接受血液透析。TAVI即刻成功率100%(18/18)。TAVI过程中1例发生心脏压塞而转外科治疗;1例因中度瓣周漏而植入另1枚瓣膜。治疗后3例存在轻度瓣周漏,1例因三度房室传导阻滞而植入永久性心脏起搏器。未见严重并发症。治疗后即刻及1、3个月,超声心动图显示主动脉瓣口流速[(203.47±70.65)、(219.64±67.49)、278.00(188.50,289.00)cm/s]和跨瓣压差[(17.16±14.05)、0(0,20.50)、12.00(0,32.50)mmHg]均较治疗前[470.50(428.75,553.25)cm/s、79.50(53.25,112.50)mmHg]降低(P均<0.05)。治疗后3个月内无死亡、卒中、急性冠脉综合征及新发房颤等严重心血管事件发生。结论 TAVI治疗重度AS安全,且短期疗效好。
英文摘要:
      Objective To observe the effect of transcatheter aortic valve implantation (TAVI) for treating severe aortic stenosis (AS). Methods Data of 18 patients with severe AS who underwent TAVI were retrospectively analyzed. The immediately success rate of TAVI was recorded, and the intraoperative and postoperative complications were observed. The valve function was evaluated, and cardiovascular events during 1 month’ and 3 months’ following-up period after treatment were recorded. Results Among 18 cases, 3 patients with coronary heart disease were treated with one-step TAVI+percutaneous coronary intervention (PCI), 2 with high risk of coronary artery occlusion were treated under “chimney” or “windowing” stent pre-protection, 1 with refractory heart failure was treated with TAVI under protection of extracorporeal membrane oxygenator (ECMO),while 1 case with uremia underwent hemodialysis on the day before TAVI and the day of TAVI after interventional procedures. The immediate operation success rate of TAVI was 100% (18/18). During treatment, 1 case was transferred to surgery due to cardiac tamponade, another valve implantation was performed in 1 case since moderate perivalvular leakage after implantation of the first valve. Mild perivalvular leakage was found in 3 cases after treatment. Implantation of permanent pacemaker was performed in 1 patient for third degree atrioventricular block. No other serious complication occurred. Immediately, 1 month and 3 months after treatment, aortic orifice flow rate ([203.47±70.65], [219.64±67.49], 278.00 [188.50, 289.00] cm/s) and pressure gradient ([17.16±14.05], 0 [0, 20.50], 12.00[0, 32.50] mmHg) showed by echocardiography decreased compared to those before treatments (470.50[428.75, 553.25] cm/s, 79.50 [53.25, 112.50] mmHg) (all P<0.05). No severe cardiovascular event, such as death, stroke, acute coronary syndrome nor new onset atrial fibrillation occurred within 3 months after treatment. Conclusion TAVI was safe for treating severe AS with good short-term efficacy.
查看全文  查看/发表评论  下载PDF阅读器
关闭